



EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS)
EUROPEAN ACCREDITATION COUNCIL ON CME (EACCME®)

RUE DE L'INDUSTRIE 24, BE- 1040 BRUSSELS
T + 32 2 649 51 64 - F + 32 2 640 37 30
<https://eaccme.uems.eu> - accreditation@uems.eu

Conflict of Interest Disclosure Form

8th World Congress on ADHD

(to be completed by scientific/organising committee members)

NAME: Stephen Faraone

AFFILIATION: SUNY Upstate Medical University

In accordance with criterion 14 of document UEMS 2016/20 "EACCME® criteria for the Accreditation of Live Educational Events (LEEs)", all declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. Declarations also must be made readily available, either in printed form, with the programme of the LEE, or on the website of the organiser of the LEE. Declarations must include whether any fee, honorarium or arrangement for reimbursement of expenses in relation to the LEE has been provided.

DISCLOSURE

- I have no potential conflict of interest to report
- I have the following potential conflict(s) of interest to report

Type of affiliation / financial interest

Name of commercial company

Receipt of grants/research supports: Otsuka, Sunovion, Supernus, Shire/Takeda,

Receipt of honoraria or consultation fees: Arbor, Genomind, Ironshore, Otsuka, Rhodes, Tris, KenP⁺

Participation in a company sponsored speaker's bureau:

Stock shareholder: Akili, Ironshore, Genomind

Spouse/partner:

Other support (please specify): royalties from books published by Guilford Press: Straight Talk abou⁺

Stephen V. Faraone

March 30, 2021

Signature:

Date:

Stephen V. Faraone Disclosures

Long Financial:

In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from, Arbor, Genomind, Ironshore, KemPharm/Corium, Ondosis, Otsuka, Rhodes, Shire/Takeda, Supernus, and Tris. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Akili Interactive Labs, Alcobra, Aveksham, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, KemPharm, Lundbeck/Takeda, McNeil, Neurolifesciences, Neurovance, Novartis, Pfizer, Sunovion, and Vallon.

He also receives royalties from books published by Guilford Press: *Straight Talk about Your Child's Mental Health*; Oxford University Press: *Schizophrenia: The Facts*; and Elsevier: *ADHD: Non-Pharmacologic Interventions*. He is also Program Director of www.adhdinadults.com.

Direct Support

Dr. Faraone is supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 667302 and NIMH grants U01 MH109536-01, 1R01MH116037-01A1 and 1R01AG06495502